AN-2728 is a topically administered,boron-containing,anti-inflammatory compound that inhibits PDE4 activity and thereby suppresses the release of TNFalpha,IL-12,IL-23 and other cytokines.AN-2728 appears to have good therapeutic potential,although further and larger trials are required to assess the long-term safety and characterize the broad utility of this drug.AN-2728 shows potent activity both in vitro and in vivo.AN-2728 is now in clinical development for the topical treatment of psoriasis and being pursued for the topical treatment of atopic dermatitis.